Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 24, 2024 1:42pm

86 Views

Post# 36146492

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

July 19, 2024 - The Indian pharmaceutical industry’s contract manufacturing business is likely to double over the next three years as the US paves way for its Biosecure Act that aims to prohibit US federal government bodies from sourcing equipment and services from Chinese pharma companies.

“With the likely shift in manufacturing from China to India, the contract manufacturing segment will double in the next three years whereas the contract research segment is set to triple over the same time,” said Mohan Ramaswamy, co-founder and CEO of Rubix Data Sciences.and head of India's pharma industry association.

https://www.financialexpress.com/business/healthcare-us-biosecure-act-targets-china-seen-to-double-indias-pharma-contract-manufacturing-in-3-years-3557737/